CD20 is a member of the membrane-spanning 4A gene family.1 CD20 has no known ligand and plays a role in development and differentiation of B cells into plasma cells.1,2 Although its exact function is not well understood, it is thought to be involved in B cell proliferation and differentiation.2,3
CD20 is expressed on the surface of most mature B cell neoplasms and some cases of B-lymphoblastic leukemia/lymphomas, Hodgkin lymphomas, and acute myeloid leukemias.3 Studies show that about 95% of B cell leukemias and lymphomas are positive for CD20.4 CD20+ cancers respond better to treatment and are associated with better clinical outcomes.5
Learn more about modalities targeting CD20:
Search our clinical trials.
Download additional information from our resources section.
CD: cluster of differentiation.
1. National Center for Biotechnology Information. MS4A1 membrane spanning 4-domains A1 [Homo sapiens (human)]. https://www.ncbi.nlm.nih.gov/gene/931. Accessed 4/9/2019. 2. Cragg MS, Walshe CA, Ivanov AO, Glennie MJ. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun. 2005;8:140-174. 3. Naeim F, Song SX, Grody WW. Principles of Immunophenotyping. In: Naeim F, Song SC, Grody WW, eds. Atlas of Hematopathology: Morphology, Immunophenotype, Cytogenetics, and Molecular Approaches. 1st ed. Burlington, MA: Academic Press; 2013. 4. Delgado J, Matutes E, Morilla AM, et al. Diagnostic significance of CD20 and FMC7 expression in B-cell disorders. Am J Clin Pathol. 2003;120(5):754-759. 5. Johnson NA, Boyle M, Bashashati A, et al. Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival. Blood. 2009;113(16):3773-3780.